Findings

What do systematic reviews say?

3 questions · 3 findings · 2 reviews · Gynaecology and Fertility

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Drospirenone plus ethinylestradiol vs placebo

Withdrawals due to adverse events · women with premenstrual syndrome (most met DSM‐V criteria for premenstrual dysphoric disorder (PMDD))

Drospirenone plus ethinylestradiol may leads to higher withdrawal due to adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral contraceptives containing drospirenone for premenstrual syndrome 2023 · Cochrane Headline outcomes only
OR 3.41 [2.01, 5.78]
4 studies · 776 participants
Low

Oestrogen in combination with progestogen (sequential or continuous) vs placebo

Withdrawals due to adverse events · women with PMS

It is very uncertain whether oestrogen in combination with progestogen (sequential or continuous) changes withdrawal due to adverse events over 2 to 4 menstrual cycles1 compared with placebo (very low certainty).

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
RR 0.64 [0.26, 1.58]
3 studies · 196 participants
Very low

Oestrogen vs placebo

Withdrawals due to adverse events · women with PMS

1 finding from 1 review

Non‐contraceptive oestrogen‐containing preparations for controlling symptoms of premenstrual syndrome 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 11 participants
Very low